02496 YZYBIO-B
- 8.360
- -0.020-0.24%
YZYBIO-B News
Tomoshiba Bio-B proposes to adopt the 2024 H-share share option plan
Youzhi YouBio-B (02496) issued an announcement. On May 29, 2024, the board of directors resolved to adopt the 2024 H share option plan in accordance with Chapter 17 of the Listing Rules for shareholders' approval at the company's annual general meeting of shareholders to be held on June 27 (Thursday) 2024. The purpose of the 2024 H share option plan is to: recognize and acknowledge the contributions that eligible participants have made or may have made to the Group; enhance the enthusiasm and loyalty of eligible participants to promote the long-term development of the enterprise and enhance shareholder value; and establish the sharing of interests among employees, shareholders and the company
Tomoshiba Biological-B (02496.HK) proposes to adopt the 2024 H share option plan
Gelonghui, May 29 | Youzhiyou Bio-B (02496.HK) announced that on May 29, 2024, the board of directors decided to recommend the 2024 H share option plan in accordance with Chapter 17 of the Listing Rules for shareholders' approval at the company's annual general meeting of shareholders to be held on June 27, 2024.
Tomoshibayu Biological-B (02496.HK): M701 malignant ascites phase II study data presented at 2024 ASCO conference
Gelonghui, May 24 | Youzhiyou Bio-B (02496.HK) announced that the mid-term analysis data of the Phase I clinical study (“this study”) of the company's self-developed epithelial cell adhesion molecule (“epCAM”) and differentiation cluster 3 (“CD3") dual-targeted bispecific antibody (“BsAb”) drug M701 in China to treat malignant ascites caused by advanced epithelial solid tumors (“this study”) was presented in the 2024 American Society of Clinical Oncology (“ASCO”) abstract meeting in the form of a poster discussion ID: 12060, Poster No.: 189), will also be carried out by the company
友芝友生物-B：2023年度報告
YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Tomoshibayu Bio-B (02496.HK): Phase III clinical trial of the bispecific antibody M701 malignant ascites completed the first patient enrollment
On March 27, Ge Longhui | Youzhiyou Bio-B (02496.HK) announced that M701, an investigational bispecific antibody (“BsAb”) that targets both epithelial cell adhesion molecule (“epCAM”) and differentiation cluster 3 (“CD3”) independently developed by the company, recently completed the first case of patients enrolled in a critical phase III registered clinical trial (“malignant ascites study”). The purpose of the malignant ascites study was to evaluate the efficacy and safety of peritoneal perfusion M701 compared with abdominal puncture drainage in patients with malignant ascites caused by advanced solid epithelial tumors. If successful, malignant ascites research will be used to support
Tomoshibayu Bio-B (02496): Phase II clinical trial of the bispecific antibody M701 malignant pleural effusion completed the first patient enrollment
Tomoshibayu Bio-B (02496) announced that the company's self-developed epithelial cell adhesion molecule (epCAM)...
Tomoshiba Biological-B (02496.HK) plans to hold a board meeting on March 28 to approve annual results
Gelonghui March 15 | YouzhiYouBio-B (02496.HK) announced that the board of directors announced that a board meeting will be held on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to deal with other matters.
Double Anti-Aura Can't Save YouZhiyou Biotech - B (02496): The stock price dropped after half a year of listing, and the cornerstone duvet cover
As of February 20 this year, the company's stock price was only HK$8.74, down 45.38% from the issue price. This is clearly far below the subscription price of Cornerstone Investors during the IPO stage. Today, it is only one month until the listing ban is lifted on March 24 this year.
Tomoshiba Biological-B (02496.HK) issues 848,000 shares due to partial exercise of over-allotment rights
On October 25, GLONGHUI | YouzhiYouBio-B (02496.HK) issued an announcement to issue and allocate 848,000 H shares due to partial exercise of over-allotment rights on October 24, 2023.
It has been abandoned by the market for a month after listing. What happened to Tomoshiba Bio (02496)?
2023 is the company's first year of listing, and in less than a month, Tomochiba Bio has been brutally “abandoned” by market capital. What exactly happened behind this?
Yuzhiba Bio-B (02496.HK): Partial exercise of over-allotment rights, price stabilization actions, and end of the price stabilization period
Glonghui, Oct. 19丨Tomochibio-B (02496.HK) announced that on October 18, 2023, the overallotment rights described in the prospectus have been partially exercised by the overall coordinator (for themselves and the international underwriter), involving a total of 848,000 H shares, equivalent to about 7.71% of the total number of shares initially available for subscription for sale under the global offering (before exercising any over-allotment rights) to supplement the overallocation of international offerings. Each H share is HK$16.00. The price stability period associated with the global sale ended on October 18, 2023, and was submitted to Hong Kong for public release
YZYBIO-B: 2023 INTERIM REPORT
YZYBIO-B: Date of Board Meeting
Youzhiyou Bio-B, from Wuhan, Hubei, was successfully listed in Hong Kong
On September 25, 2023, Wuhan Youzhiyou Biopharma Co., Ltd. (hereinafter referred to as “Youzhiyou Biotech”) (02496.HK) was successfully listed on the main board of the Hong Kong Stock Exchange.
YZY Biopharma Shares to Start Trading on the Hong Kong Stock Exchange on Sept. 25
YZY Biopharma Shares to Start Trading on the Hong Kong Stock Exchange on Sept. 25
YZY Biopharma IPO Price at Lower End of the Guided Range of Between HK$16.00-HK$20.00/Share
YZY Biopharma IPO Price at Lower End of the Guided Range of Between HK$16.00-HK$20.00/Share
Understand Tomoshibatomo Bio-B (02496.HK) IPO in one picture
It is expected to be listed on the main board of the Stock Exchange on September 25, 2023
Tomoshibatomo Bio-B (02496.HK) plans to sell 1.10.12 million H-shares globally and introduce multiple cornerstones such as Optics Valley Health
GLONGHUI September 13 | Youzhiyou Bio-B (02496.HK) announced that the company plans to sell 1.0.012 million H shares globally, including 1.102,200 shares sold in Hong Kong, 9.01 million shares sold internationally, and another 15% over-allotment rights; the expected pricing date is September 18; the sale price will be HK$16.00-20.00 per share, 200 shares per lot, with an entry fee of about HK$4040; CITIC Construction Investment is expected to be the exclusive sponsor; The shares will be On 2023/9/25
Analysis
Price Target
No Data
